XtalPi expands AI-driven chemistry platform for drug discovery

By AI, Created 5:22 AM UTC, May 29, 2026, /AGP/ – XtalPi says it has built a digital, automated and AI-driven chemistry platform to speed drug discovery as biopharma R&D faces rising costs and slower productivity. The company says the platform now supports more than 200 biopharma clients worldwide and is designed to move chemistry work from synthesis planning to delivery with less manual effort.

Why it matters: - XtalPi is positioning chemistry infrastructure as a bottleneck to drug discovery speed, cost and scale. - The company says biopharma R&D is under pressure from rising costs, shorter product lifecycles and a 4.1% IRR for top pharma companies. - XtalPi is targeting both the speed of making individual molecules and the number of projects chemists can run at once. - The platform is designed to reduce trial-and-error, shorten turnaround times and improve workflow efficiency across discovery chemistry.

What happened: - XtalPi said it has built a fully integrated digital, automated and AI-driven chemistry platform for scalable drug discovery. - The company said its chemical synthesis services launched in early 2021. - XtalPi said it now has nearly 400 experts and serves more than 200 biopharmaceutical clients worldwide. - The company said its client retention rate has stayed above 90% over the past two years. - XtalPi said the platform supports medicinal chemistry, synthetic chemistry, analytical chemistry and compound management.

The details: - XtalPi said its platform uses a short-term strategy to remove horizontal bottlenecks and a long-term strategy to address vertical bottlenecks. - The Orbit digital platform is built to create collaborative, specialized workflows that let teams advance more projects in parallel. - XtalPi said it is developing next-generation automated experimental equipment and AI algorithms to cut molecule synthesis time from weeks to days. - The workflow includes preparation, reaction, monitoring, workup, purification, freeze-drying, quality control, delivery and final report generation. - XtalPi said its preparation tools include AI-powered synthesizability prediction, reaction-condition recommendations and interactive retrosynthesis. - The Synthesis-LCMS Integrated Workstation supports high-throughput reaction execution at 8mL x 72 or 40mL x 36, with automated sample preparation and data capture. - XtalPi said real-time queue monitoring, AI-driven LC-MS spectrum reading and centralized automated post-workup cut processing time by 30%. - The company said centralized purification platforms use a “1+3” model controlling 10 to 12 column machines and can operate unattended overnight. - XtalPi said its PAD one-code solution provides full lifecycle traceability, and 60% of deliveries move through that streamlined pipeline. - Automated ELN record verification and report writing are designed to reduce documentation work. - XtalPi said its digital tools include centralized post-processing, centralized purification and the PAD one-code system. - The company said 30% of post-synthesis tasks are centrally managed, 50% of purification work is completed through centralized MPLC control and 60% of deliveries use PAD. - XtalPi said its workstation handles temperatures from room temperature to 140°C and is integrated with its ELN. - The company said its AI models cover more than 23 reaction types, with a success rate above 85% for synthesizability prediction and reaction-condition recommendations. - XtalPi said its HTE-based models are used for reaction-condition recommendation and yield prediction in client projects. - The company said AI-driven LC-MS spectrum reading enables autonomous judgment and readout for more than 70% of samples. - XtalPi said it has more than 300 synthetic chemists, including 63% with master’s degrees or above and 80% with more than four years of synthesis experience. - The company said it has 5,000 square meters of traditional lab space and 4,000 square meters of automated lab space across Shanghai and Shenzhen. - XtalPi said it offers FTE and FFS service models, plus custom synthesis for ADC/RDC, PROTACs, molecular glues, peptides, lipids and other specialty chemistry. - The company said its AI-with-robotics-aided library synthesis combines AI, automation and human expertise for focused or diversity-oriented libraries.

Between the lines: - XtalPi is making a broader case that chemistry operations, not just discovery biology, can be digitized and industrialized. - The emphasis on workflow integration suggests the company is competing on throughput, traceability and consistency as much as on scientific expertise. - The repeated focus on automation and AI reflects a market where biopharma executives increasingly view scalable data-driven R&D as a competitive necessity.

What’s next: - XtalPi said it will keep expanding its AI coverage to more reaction types. - The company said it will continue developing automated equipment and AI models to further reduce synthesis time. - XtalPi is likely to keep pushing its integrated platform as a service offering for biopharma teams seeking faster chemistry execution.

The bottom line: - XtalPi is trying to turn drug-discovery chemistry into a software-and-automation problem, not just a manual lab process.